One of those compounds, TAK-637 (figure 6), underwent phase II clinical trials for urinary incontinence, depression and irritable bowel syndrome, but the development was discontinued.
Jedno od tih jedinjenja, TAK-637 (slika 6), je bilo u fazi II kliničkih ispitivanja za urinarnu inkontinenciju, depresiju i upalnu bolest creva, ali je razvoj prekinut.